Register for free to
view the full innovation profile.
Our OmniDerm tech allows for the passive delivery of antihistamines like Benadryl, Claritin, Reactine etc directly through the skin over an extended time period.
About
Avro Life Science has developed a novel material for transdermal drug delivery of multiple small molecule drugs, across a wide range of therapeutic categories including cardiovascular health, neuroscience, diabetes, consumer health, and more. Patches made with this patent-pending technology have many advantages: • They are small (~1” dia.), thin, and commercially feasible from a consumer use point of view • They are composed of inexpensive biomaterials and can be manufactured in a cost-effective manner, ensuring appreciable profit margins • Ex vivo studies have revealed their versatility in delivering a variety of therapeutic molecules for vastly different medical conditions. Utilization of transdermal technology opens an entirely new differentiated value-add revenue stream through simple alteration of delivery mechanism • The use of this new technology increases market share in the pediatric, elderly, and disabled populations, providing an alternative method of drug delivery over competitors; patches are clinically proven to be effective in increasing compliance, reducing side effects, increasing bioavailability, and reducing the need to re-dose medicine • Oral medication compliance rates are consistently decreasing, and market data indicates that innovative drug delivery solutions will provide a highly profitable solution to this issue Our team has witnessed the issues experienced in the administration of allergic rhinitis medications to a number of patient groups, especially the pediatric and geriatric populations. As both of Avro's cofounders experience allergic rhinitis, it was one of the first patches that we tested, with great success. We are currently looking for a partner for our patch technology which is capable of passively delivering a number of different anthistamines through the skin, like Benadryl, Claritin, Reactine, and more. Independent market research and communication with pharmacies, parents and clinicians has indicated the need for additional transdermal technology which will ease the medication process for children, the elderly and the disabled, increasing patient compliance, and increasing convenience for parents and caregivers, at a reasonable price point. The team is engaged with various therapeutic manufacturers and pharmacy chains exploring potential proof of concept, co-development, licensing and white-labeling arrangements which may be mutually beneficial, by providing pharma partners with early data relating to Avro’s novel technology in exchange for their support in bringing the product to market and penetrating the transdermal space. Avro’s platform technology allows for pharmaceutical partners to easily integrate transdermal technology across an already-existing large pipeline of small molecules while minimizing internal development costs due to reformulation, and provides a differentiating dosage form for future product launches, while providing patent extension opportunities for on-patent products and pipeline products. Avro’s technology addresses the previous issues found in transdermal tech – they are small with a high drug loading capacity, extremely cost-effective at scale, easy to manufacture, and exhibit sweat resistant, water resistant, anti-microbial, non-residual and non-irritant properties. The material is also versatile, allowing for the delivery of many different small molecules with minimal reformulation, in contrast to current patches/materials on the market which require customization or a “lock and key” model. The core chemistry can be feasibly scaled for industrial manufacturing and full-scale production using simple industry procedures. The patch’s components can be easily sourced and synthesized, allowing for cost- effective production at industrial scale. Finally, these patches may be used to deliver drugs transdermally which may not be effective in oral forms due to low bioavailability, gastrointestinal complications, significant side effects and more, opening exclusive pathways for bringing lucrative drugs to market that may not have passed clinical trials in oral forms. The patches are currently capable of delivering drugs consistently over a 24 hour period, and are in the late stages of R&D for 3 day or 72 hour patches, to increase convenience and compliance among patient populations and provide a steady delivery profile of therapeutics over an extended time period.
Key Benefits
The transdermal delivery of a number of different antihistamines can provide a wide variety of benefits, depending on the drug of choice. In most cases, delivering these drugs transdermally will eliminate a number of the compliance issues associated with administering medications orally, especially in pediatric populations (considering that patches can be developed in attractive form factors with appealing designs, replacing a pill with a Star Wars medicated sticker etc). Beyond the compliance benefits, in many cases the transdermal administration and avoidance of first pass metabolism can reduce side effects, and potentially increase the bioavailability or total amount of drug effectively absorbed by the body. The transdermal delivery form is also highly differentiated from other delivery forms (pills and syrups), and as such, can likely be marketed at a slightly higher price, accounting for the convenience afforded to patients. Finally, for extended release patches (3-7 days), their use would be convenient to patients who constantly suffer during peak allergy seasons, and eliminate the need to constantly redose pills, especially for those with short half lives like Benadryl.
Applications
This technology is broadly applicable across the vast majority of small molecules with molecular weights under 600 Daltons and daily dosages of under 200mg.